With predictive algorithms, the platform is designed to help clinicians proactively address instability in blood flow and pressure in critical situations.
BD (Becton, Dickinson and Company) has launched a new hemodynamic monitoring platform with predictive artificial intelligence (AI)-based algorithms designed to help clinicians proactively address blood pressure instability and optimize blood flow to help avoid potential life-threatening situations during procedures.
The company says HemoSphere Alta platform is its most advanced hemodynamic monitoring technology available. One of the key innovations is the new Cerebral Autoregulation Index, a parameter that indicates whether the brain is likely to maintain stable blood flow despite changes in blood pressure and offers personalized insights into a patient’s blood pressure requirements. Clinicians can access Cerebral Autoregulation Index when using a noninvasive ForeSight IQ Sensor, placed on the patient’s forehead, combined with an Acumen IQ Sensor, connected to the patient’s arterial line.
The HemoSphere Alta platform also includes the Acumen Hypotension Prediction Index software that predicts when a patient could have a low blood pressure event, which has been demonstrated to reduce the depth, duration, and severity of hypotension in several large multicenter studies.
“Research over the past two decades has demonstrated the wide variability of the lower limit of cerebral blood flow autoregulation between individuals, as well as the risk for patient morbidity and mortality when blood pressure is maintained below this threshold,” says Charles Hogue, MD, chairman of the department of anesthesiology at Northwestern University Feinberg School of Medicine in Chicago, in a release. “The availability of the novel Cerebral Autoregulation Index provides clinicians with a tool to detect conditions of impaired autoregulation and can help identify a patient’s lower limit of autoregulation. This, in combination with Hypotension Prediction Index technology and other advanced software and algorithms on the HemoSphere Alta platform allows us to both customize and predict patients’ low blood pressure.”
The new monitor also features an improved design to streamline the user experience, including a larger 15-inch high-resolution, customizable touchscreen display, split-screen views, and is designed to minimize disruptive pop-ups. Voice and gesture command features are designed to help maintain sterility and allow for hands-free interaction with the monitor, such as silencing alarms and switching views.
“HemoSphere Alta marks the latest milestone in our continuum of connected care innovations by redefining the clinician experience with more efficient workflows and increased usability,” says Tim Patz, president of BD Advanced Patient Monitoring, in a release. “These AI-driven enhancements of advanced algorithms and machine learning provide clinicians with more insights and clinical decision support to help improve the quality of care for their patients.”
The platform received US Food and Drug Administration clearance in December 2024.
Photo caption: The HemoSphere Alta platform is BD’s most advanced hemodynamic monitoring technology.
Photo credit: BD
